751 related articles for article (PubMed ID: 25355590)
1. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
[TBL] [Abstract][Full Text] [Related]
2. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
[TBL] [Abstract][Full Text] [Related]
3. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
[TBL] [Abstract][Full Text] [Related]
4. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
5. Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF.
Scheinhardt MO; Lerman T; König IR; Griesinger G
Hum Reprod; 2018 Aug; 33(8):1499-1505. PubMed ID: 30007353
[TBL] [Abstract][Full Text] [Related]
6. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
[TBL] [Abstract][Full Text] [Related]
7. Cumulative live birth rates in low-prognosis women.
Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
[TBL] [Abstract][Full Text] [Related]
8. Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol.
Broekmans FJ; Verweij PJ; Eijkemans MJ; Mannaerts BM; Witjes H
Hum Reprod; 2014 Aug; 29(8):1688-97. PubMed ID: 24903202
[TBL] [Abstract][Full Text] [Related]
9. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
[TBL] [Abstract][Full Text] [Related]
10. Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?
Oudshoorn SC; van Tilborg TC; Hamdine O; Torrance HL; Eijkemans MJC; Lentjes EGWM; Lambalk CB; Broekmans FJM
Hum Reprod; 2017 Aug; 32(8):1701-1709. PubMed ID: 28854580
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
12. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
13. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study.
Depmann M; Eijkemans MJ; Broer SL; Scheffer GJ; van Rooij IA; Laven JS; Broekmans FJ
Hum Reprod; 2016 Jul; 31(7):1579-87. PubMed ID: 27179263
[TBL] [Abstract][Full Text] [Related]
14. ESHRE guideline: ovarian stimulation for IVF/ICSI
Ovarian Stimulation TEGGO; Bosch E; Broer S; Griesinger G; Grynberg M; Humaidan P; Kolibianakis E; Kunicki M; La Marca A; Lainas G; Le Clef N; Massin N; Mastenbroek S; Polyzos N; Sunkara SK; Timeva T; Töyli M; Urbancsek J; Vermeulen N; Broekmans F
Hum Reprod Open; 2020; 2020(2):hoaa009. PubMed ID: 32395637
[TBL] [Abstract][Full Text] [Related]
15. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554
[TBL] [Abstract][Full Text] [Related]
16. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
17. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
18. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
19. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
[TBL] [Abstract][Full Text] [Related]
20. Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study.
Dólleman M; Verschuren WM; Eijkemans MJ; Broekmans FJ; van der Schouw YT
Hum Reprod; 2015 Aug; 30(8):1974-81. PubMed ID: 26082477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
